Add-On Effect of Simultaneous Intravitreal Dexamethasone to Intravitreal Bevacizumab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

Limon, Utku; Akçay, Betül İlkay Sezgin

doi:10.1089/jop.2021.0100

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the primary objectives (BCVA improved at month 12), a sample size of 90%, a two-sided alpha level of 0.05, and a dropout rate of 10% were calculated using the PASS software version 15.0. According to previous reported, at the 12-month follow-up time point after combined treatment with DEX-I and intravitreal IVR, BCVA improved by a mean of 21.3 letters in naïve patients [20] and by a mean of 9.8 letters in refractory patients [15], with a maximum standard deviation of 13.3 letters [15, 20, 21]. Therefore, the nal sample size was determined to be 33 cases per group.…”

Section: Discussionmentioning

confidence: 99%

The effect of simultaneous intravitreal Ranibizumab and intravitreal extended-release dexamethasone injection on patients with naïve versus refractory retinal vein occlusion macular edema: prospective, single-center, interventional, and open-label study

Sun

Meng

et al. 2023

Preprint

View full text Add to dashboard Cite

Background The efficacy of concurrent intravitreal Ranibizumab (IVR) and extended-release dexamethasone injections (Dex-I) in patients with naïve and refractory retinal vein occlusion macular edema (RVO-ME) was not well investigated previously. Methods This was a prospective, interventional, and open-label case series design. There were two groups: naïve and refractory patients (received ≥ 5 times of previous IVR within one year prior to enrollment) enrolled. Patients received IVR and Dex-I concurrently. IVR and Dex-I were given PRN. The mean change in best-corrected visual acuity (BCVA) was measured as main outcome. Results 63 patients (63 eyes) completed the entire follow-up (31 naïve and 32 refractory patients). At month 12, the change in BCVA was greater in the naïve group than in the refractory group (19.67 ± 11.7 (95%CI: 15.03,24.31) letters vs. 11.74 ± 11.18 (95%CI:7.32,16.16) letters, P = 0.014). There was no difference between the two groups of mean macular thickness reduction. (364.26 ± 215.29 (95%CI: 279.09,449.43)µm v.s. 410.19 ± 204.34 (95%CI: 329.35,491.02)µm, P = 0.43). The mean co-injection numbers were 2.52 ± 0.58 (95%CI:2.29,2.75) and 2.33 ± 0.55(95%CI:2.11,2.55) in both groups (P = 0.24). The retreatment interval was 115.81 ± 13.79 (95%CI: 110.36,121.27) days and 122.74 ± 14.06(95%CI: 119.93,133.56) days in both groups (P = 0.073). There was no significant difference in the incidence of glaucoma or the progression of cataracts between the two groups. Conclusion In both naïve and refractory RVO-ME patients, IVR combined with Dex-I was effective. The initial combination therapy for naïve patients demonstrated more efficient improvement in BCVA and may reduce total injection numbers. Trial registration: this study was registered with the identifier ChiCTR-INR-17011877 at https://www.chictr.org.cn/

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of simultaneous intravitreal Ranibizumab and intravitreal extended-release dexamethasone injection on patients with naïve versus refractory retinal vein occlusion macular edema: prospective, single-center, interventional, and open-label study

Sun

Meng

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Relationship between retinal volume changes and the prognosis of BRVO-ME treated with ranibizumab

Xing,

Liu,

Sun

et al. 2024

Heliyon

View full text Add to dashboard Cite

Retinal Vein Occlusion–Background Knowledge and Foreground Knowledge Prospects—A Review

Lendzioszek,

Bryl,

Poppe

et al. 2024

JCM

View full text Add to dashboard Cite

Thrombosis of retinal veins is one of the most common retinal vascular diseases that may lead to vascular blindness. The latest epidemiological data leave no illusions that the burden on the healthcare system, as impacted by patients with this diagnosis, will increase worldwide. This obliges scientists to search for new therapeutic and diagnostic options. In the 21st century, there has been tremendous progress in retinal imaging techniques, which has facilitated a better understanding of the mechanisms related to the development of retinal vein occlusion (RVO) and its complications, and consequently has enabled the introduction of new treatment methods. Moreover, artificial intelligence (AI) is likely to assist in selecting the best treatment option for patients in the near future. The aim of this comprehensive review is to re-evaluate the old but still relevant data on the RVO and confront them with new studies. The paper will provide a detailed overview of diagnosis, current treatment, prevention, and future therapeutic possibilities regarding RVO, as well as clarifying the mechanism of macular edema in this disease entity.

show abstract

Add-On Effect of Simultaneous Intravitreal Dexamethasone to Intravitreal Bevacizumab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

Cited by 3 publications

References 15 publications

The effect of simultaneous intravitreal Ranibizumab and intravitreal extended-release dexamethasone injection on patients with naïve versus refractory retinal vein occlusion macular edema: prospective, single-center, interventional, and open-label study

The effect of simultaneous intravitreal Ranibizumab and intravitreal extended-release dexamethasone injection on patients with naïve versus refractory retinal vein occlusion macular edema: prospective, single-center, interventional, and open-label study

Relationship between retinal volume changes and the prognosis of BRVO-ME treated with ranibizumab

Retinal Vein Occlusion–Background Knowledge and Foreground Knowledge Prospects—A Review

Contact Info

Product

Resources

About